Artículo
What are the effects of pregabalin add-on for people with drug-resistant focal epilepsy?
Fecha de publicación:
10/2019
Editorial:
Wiley
Revista:
Cochrane Clinical Answers
ISSN:
2050-4217
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Compared with placebo for adolescents and adults with drug‐resistant focal epilepsy taking up to five antiepileptic drugs (AEDs), low‐certainty evidence suggests that more people may achieve a 50% or greater reduction in seizure frequency with pregabalin within 12 to 17 weeks (319 vs 140 per 1000 people; all results on average). Moderate‐certainty evidence shows that more people will probably be seizure‐free with pregabalin, although the absolute numbers of people benefiting are likely to be small (28 vs 7 per 1000 people). Moderate‐certainty evidence also shows that more people taking pregabalin are likely to withdraw from treatment (for any reason or due to an adverse effect; 47 and 102 additional withdrawals per 1000 people, respectively) and/or to experience ataxia, dizziness, somnolence, and weight gain (89, 193, 95, and 82 additional events per 1000 people).
Palabras clave:
SALUD
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(CIESP)
Articulos de CENTRO DE INVESTIGACIONES EN EPIDEMIOLOGIA Y SALUD PUBLICA
Articulos de CENTRO DE INVESTIGACIONES EN EPIDEMIOLOGIA Y SALUD PUBLICA
Citación
Ciapponi, Agustín; What are the effects of pregabalin add-on for people with drug-resistant focal epilepsy?; Wiley; Cochrane Clinical Answers; 10-2019; 1-14
Compartir
Altmétricas